Skip to main content
AARD
NASDAQ Life Sciences

FDA Imposes Full Clinical Hold on Lead Drug ARD-101, Halting Phase 3 Trials

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$6.1
Mkt Cap
$146.824M
52W Low
$3.35
52W High
$17.94
52W Position info
82% above low
Off High info
66% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

AARD sits 82% above its 52-week low of $3.35.

Summary

Aardvark Therapeutics announced that the FDA has placed a full clinical hold on its lead investigational drug, ARD-101, halting all ongoing clinical studies, including Phase 3 trials for Prader-Willi Syndrome.


Key Events · Product Development and Regulatory · AARD

  • FDA Imposes Full Clinical Hold

    The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on Aardvark Therapeutics' investigational new drug application (IND) for ARD-101.

  • Phase 3 Trials Halted

    The clinical hold applies to all ongoing studies under the IND, including the Phase 3 HERO trial and the open-label extension (OLE) trial for Prader-Willi Syndrome.

  • Follows Voluntary Pause

    This regulatory action follows the company's previously announced voluntary pause in its Phase 3 trials due to safety observations.

  • Company to Unblind Data

    Aardvark Therapeutics plans to unblind clinical data from both trials to assess efficacy and safety, informing next steps for the ARD-101 program.


Analysis · AARD · Life Sciences

The FDA's decision to place a full clinical hold on ARD-101 is a critical setback for Aardvark Therapeutics, as it directly impacts their lead drug candidate in Phase 3 trials for Prader-Willi Syndrome. This escalates the previously announced voluntary trial pauses to a regulatory mandate, casting significant doubt on the program's future and the company's primary value driver. While the company plans to unblind data and engage with the FDA, the hold represents a major blow to investor confidence and the company's ability to bring ARD-101 to market.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AARD was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.8M. The 52-week trading range was $3.35 to $17.94. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AARD - Latest Insights

AARD
Nov 13, 2026, 8:18 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.42 info
Change: -$0.0997 (-7%) info
Market Cap: $29.107M info
AARD
Nov 13, 2026, 7:47 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.42 info
Change: -$0.100 (-7%) info
Market Cap: $29.107M info
AARD
Nov 12, 2026, 7:56 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.42 info
Change: -$0.090 (-6%) info
Market Cap: $29.107M info
AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.42 info
Change: -$1.67 (-54%) info
Market Cap: $29.107M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $1.42 info
Change: -$2.53 (-64%) info
Market Cap: $29.107M info